23 June 2009
Antibody response to influenza vaccine in coronary artery disease: a substudy of the FLUCAD study
Lidia B. BrydakADF, Magdalena RomanowskaCDE, Iwona NowakBC, Andrzej CiszewskiBG, Zofia T. BilinskaBMed Sci Monit 2009; 15(7): PH85-91 :: ID: 869693
Abstract
Background
Influenza vaccination is recommended for patients with cardiovascular diseases. The main reason for the low vaccination rates in such patients is insufficient knowledge about vaccination efficacy, including immune response to the vaccine. The aim of this study was to assess humoral response to influenza vaccination in patients with coronary artery disease.
Material and Method
This was a substudy of the randomized prospective double-blind placebo-controlled FLUCAD study on influenza vaccination in the secondary prevention of ischemic coronary events in patients with coronary artery disease. Patients received inactivated subunit vaccine (n=325) or placebo (n=333). Anti-hemagglutinin and anti-neuraminidase antibody levels to the vaccine strains as well as IgM and IgG levels against influenza A and B were measured before administration of vaccine/placebo and after 8-10 weeks in 78 vaccinated and 97 placebo patients.
Results
Post-vaccination antibody titers were significantly higher than before vaccination, with mean increases of 4.9- to 5.7-fold for anti-hemagglutinin and 3.5- to 4.2-fold for neuraminidase antibodies. Post-vaccination protection rates ranged from 56.4 to 60.3% and response rates from 62.8 to 68%. The percentage of patients with significant post-vaccination concentrations of IgG and IgM was higher than before vaccination and amounted to 100% and 88.1% in the case of IgG and 14.3% and 5.2% in the case of IgM in response to influenza A and B, respectively.
Conclusions
At least 60% of the patients achieved high post-vaccination antibody levels sufficient to prevent influenza.
Keywords: Influenza Vaccines - immunology, Double-Blind Method, Hemagglutinin Glycoproteins, Influenza Virus - immunology, Coronary Artery Disease - immunology, Antigens, Viral - immunology, Antibody Formation - immunology, Antibodies, Viral - immunology, Aged, 80 and over, Neuraminidase - immunology, Orthomyxoviridae - immunology
Editorial
04 June 2022 : Editorial
Editorial: Acute Hepatitis of Unknown Origin in Children. Is Autoimmunity at Play?DOI: 10.12659/MSM.937371
Med Sci Monit 2022; 28:e937371
In Press
27 Jun 2022 : Clinical Research
Automatic Identification of Depression Using Facial Images with Deep Convolutional Neural NetworkMed Sci Monit In Press; DOI: 10.12659/MSM.936409
23 Jun 2022 : Clinical Research
A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, w...Med Sci Monit In Press; DOI: 10.12659/MSM.936706
22 Jun 2022 : Clinical Research
A Single-Center Study Comparing the Effects of Thoracic Spine Manipulation vs Mobility Exercises in 26 Offi...Med Sci Monit In Press; DOI: 10.12659/MSM.937316
21 Jun 2022 : Clinical Research
Optimal Timing and Outcomes of Minimally Invasive Approach in Acute Biliary PancreatitisMed Sci Monit In Press; DOI: 10.12659/MSM.937016
Most Viewed Current Articles
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292
01 Nov 2020 : Review article
Long-Term Respiratory and Neurological Sequelae of COVID-19DOI :10.12659/MSM.928996
Med Sci Monit 2020; 26:e928996
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952